<p>默克公司（NYSE:MRK - 獲取免費報告）在週四收到了異常大量的期權交易。交易者購買了 177,669 份看跌期權。這比平均交易量 40,313 份看跌期權增加了約 341%。</p>
<p>獲取 <strong>默克公司</strong> 的提醒：</p>
<h2>默克公司股價下跌 1.5%</h2>
<ul>
<li>默克：購買此跌幅的 4 個不容錯過的理由</li>
</ul>
<p>週四，MRK 股票下跌 1.32 美元，報 84.35 美元。該股票的交易量為 20,375,205 股，而其平均交易量為 14,421,404 股。公司的 50 日移動平均價格為 97.82 美元，200 日移動平均價格為 105.65 美元。默克公司的 1 年最低價為 84.31 美元，1 年最高價為 134.63 美元。公司的債務與股本比率為 0.79，流動比率為 1.36，速動比率為 1.15。該公司的市值為 2133.7 億美元，市盈率為 12.53，市盈增長比率為 0.83，貝塔值為 0.38。</p>
<p>默克公司（NYSE:MRK - 獲取免費報告）上一次發佈季度財報是在 2 月 4 日，報告顯示該季度每股收益為 1.72 美元，低於市場共識預期的 1.85 美元（差 0.13 美元）。該季度的收入為 156.2 億美元，而分析師預期為 155.1 億美元。默克公司的股本回報率為 45.35%，淨利潤率為 26.67%。該公司的收入同比增長 6.8%。去年同期，該公司每股收益為 0.03 美元。分析師預計默克公司今年每股收益將達到 9.01 美元。</p>
<ul>
<li>Moderna 股價因 H5N1 新聞飆升——投資者接下來該怎麼辦？</li>
</ul>
<p>默克公司宣佈其董事會於 1 月 28 日授權了一項股票回購計劃，授權公司回購 100 億美元的流通股。該回購授權允許公司通過公開市場購買最多 4.1% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
<h2>默克公司分紅公告</h2>
<p>該公司最近宣佈了一項季度分紅，將於 4 月 7 日支付。3 月 17 日的登記投資者將獲得 0.81 美元的分紅。這相當於年化 3.24 美元的分紅，收益率為 3.84%。除息日為 3 月 17 日。默克公司的分紅支付比率（DPR）為 48.14%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>MarketBeat 週迴顧 – 11/4 - 11/8</li>
</ul>
<p>幾位研究分析師最近對該股票發表了看法。大和證券在 11 月 11 日的研究報告中將默克公司的股票評級從 “強力買入” 下調至 “持有”。TD 證券將默克公司的評級從 “買入” 下調至 “持有”，並將其目標價從 121.00 美元下調至 100.00 美元。瑞銀集團在 1 月 8 日的研究報告中將默克公司的目標價從 125.00 美元下調至 120.00 美元，並對該股票給予 “買入” 評級。摩根士丹利在 2 月 5 日的研究報告中將默克公司的目標價從 113.00 美元下調至 106.00 美元，並對該公司給予 “同等權重” 評級。最後，BMO 資本市場在 2 月 5 日的報告中將默克公司的目標價從 105.00 美元下調至 96.00 美元，並對該公司給予 “市場表現” 評級。一位股票研究分析師對該股票給予了賣出評級，十位分析師給予了持有評級，九位給予了買入評級，三位給予了強力買入評級。根據 MarketBeat 的數據，默克公司目前的共識評級為 “適度買入”，平均目標價為 117.06 美元。</p>
<p><strong>查看我們關於 MRK 的最新報告</strong></p>
<h2>內部人士下注</h2>
<p>在其他新聞中，董事 Inge G. Thulin 於 2 月 6 日的交易中購買了 2,833 股公司的股票。該股票的平均購買成本為每股 88.25 美元，總價值為 250,012.25 美元。收購完成後，該董事現在擁有 2,933 股公司的股票，價值約為 258,837.25 美元。這代表其持股增加了 2,833.00%。該交易已在證券交易委員會的法律文件中披露，可以通過 SEC 網站訪問。此外，內部人士 Cristal N. Downing 在 2 月 6 日的交易中出售了 2,361 股公司的股票。該股票的平均售價為 88.76 美元，總價值為 209,562.36 美元。交易完成後，該內部人士現在直接擁有 7,085 股公司股票，價值為 628,864.60 美元。該交易代表其持股減少了 24.99%。該銷售的披露信息可以在此找到。公司內部人士持有公司股票的 0.09%。</p>
<h2>機構投資者對默克公司的看法</h2>
<p>最近，一些機構投資者和對沖基金買賣了該股票的股份。E&amp;G Advisors LP 在第三季度將其在默克公司的持股比例提高了 0.7%。E&amp;G Advisors LP 現在擁有 14,698 股該公司的股票，價值 1,669,000 美元，此前在上個季度又購買了 100 股。馬薩諸塞州財富管理公司在第三季度將其在默克公司的股份增加了 0.4%。馬薩諸塞州財富管理公司現在擁有 22,474 股該公司的股票，價值 2,552,000 美元，此前在此期間又購買了 100 股。Shayne &amp; Jacobs LLC 在第三季度將其在默克公司的持股提高了 1.8%。Shayne &amp; Jacobs LLC 現在擁有 5,611 股該公司的股票，價值 637,000 美元，此前在上個季度又購買了 100 股。Alan B Lancz &amp; Associates Inc.在第三季度將其在默克公司的股份提高了 0.7%。Alan B Lancz &amp; Associates Inc.現在擁有 13,834 股該公司的股票，價值 1,571,000 美元，此前在此期間又購買了 100 股。最後，First Bank &amp; Trust 在第三季度將其在默克公司的股份提高了 1.1%。First Bank &amp; Trust 現在擁有 8,995 股該公司的股票，價值 1,021,000 美元，此前在此期間又購買了 101 股。76.07% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>默克公司簡介</h2>
<p>(獲取免費報告)</p>
<p>默克公司是一家醫療保健公司，提供通過處方藥、疫苗、生物治療、動物健康和消費者護理產品的健康解決方案。它通過以下幾個部門運營：製藥、動物健康和其他。製藥部門包括人類健康藥品和疫苗產品。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過默克公司。</li>
<li>學習技術分析技能，掌握股市。</li>
<li>Upstart 的上升趨勢剛剛開始：是時候加倉了。</li>
<li>投資者需要知道的擊敗市場的信息。</li>
<li>Archer Aviation 獲得黑石投資——ACHR 的下一步是什麼？</li>
<li>如何投資藍籌股。</li>
<li>巴菲特增持西方石油——堅持他的投資策略。</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 嗎？</h2>
<p>在你進行下一筆交易之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。</p>
<p>我們的團隊已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而且沒有一隻大名鼎鼎的股票在名單上。</p>
<p>他們認為這五隻股票是投資者現在應該購買的五家最佳公司……</p>
<p>查看這五隻股票</p>
<h2>你現在應該投資$1,000 在默克公司嗎？</h2>
<p>在你考慮默克公司之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而默克公司不在名單上。</p>
<p>雖然默克公司目前在分析師中有 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

默克

<p>默克公司（NYSE:MRK）經歷了顯著的看跌期權交易激增，共購買了 177,669 份期權，較平均日交易量增加了 341%。股價下跌了 1.5%，至 84.35 美元，交易量超過 2000 萬股。默克最近的季度財報顯示，收入為 156.2 億美元，略高於預期，但每股收益未能達到預期。公司還宣佈了一項 100 億美元的股票回購計劃和每季度 0.81 美元的股息，反映出對其股票價值的信心</p>

<p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) was the recipient of unusually large options trading on Thursday. Traders acquired 177,669 put options on the company. This represents an increase of approximately 341% compared to the average volume of 40,313 put options.</p>
<div class="lb-trans"><p>默克公司（NYSE:MRK - 獲取免費報告）在週四收到了異常大量的期權交易。交易者購買了 177,669 份看跌期權。這比平均交易量 40,313 份看跌期權增加了約 341%。</p>
</div><p>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>默克公司</strong> 的提醒：</p>
</div><h2>Merck &amp; Co., Inc. Trading Down 1.5 %</h2>
<div class="lb-trans"><h2>默克公司股價下跌 1.5%</h2>
</div><ul>
<li>Merck: 4 No-Brainer Reasons to Buy This Dip</li>
</ul>
<div class="lb-trans"><ul>
<li>默克：購買此跌幅的 4 個不容錯過的理由</li>
</ul>
</div><p>Shares of MRK stock traded down $1.32 on Thursday, hitting $84.35. The stock had a trading volume of 20,375,205 shares, compared to its average volume of 14,421,404. The company's 50 day moving average price is $97.82 and its 200-day moving average price is $105.65. Merck &amp; Co., Inc. has a 1 year low of $84.31 and a 1 year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm has a market capitalization of $213.37 billion, a P/E ratio of 12.53, a P/E/G ratio of 0.83 and a beta of 0.38.</p>
<div class="lb-trans"><p>週四，MRK 股票下跌 1.32 美元，報 84.35 美元。該股票的交易量為 20,375,205 股，而其平均交易量為 14,421,404 股。公司的 50 日移動平均價格為 97.82 美元，200 日移動平均價格為 105.65 美元。默克公司的 1 年最低價為 84.31 美元，1 年最高價為 134.63 美元。公司的債務與股本比率為 0.79，流動比率為 1.36，速動比率為 1.15。該公司的市值為 2133.7 億美元，市盈率為 12.53，市盈增長比率為 0.83，貝塔值為 0.38。</p>
</div><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). The business had revenue of $15.62 billion during the quarter, compared to analyst estimates of $15.51 billion. Merck &amp; Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business's revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.03 EPS. Analysts anticipate that Merck &amp; Co., Inc. will post 9.01 earnings per share for the current year.</p>
<div class="lb-trans"><p>默克公司（NYSE:MRK - 獲取免費報告）上一次發佈季度財報是在 2 月 4 日，報告顯示該季度每股收益為 1.72 美元，低於市場共識預期的 1.85 美元（差 0.13 美元）。該季度的收入為 156.2 億美元，而分析師預期為 155.1 億美元。默克公司的股本回報率為 45.35%，淨利潤率為 26.67%。該公司的收入同比增長 6.8%。去年同期，該公司每股收益為 0.03 美元。分析師預計默克公司今年每股收益將達到 9.01 美元。</p>
</div><ul>
<li>Moderna Shares Spike on H5N1 News—What’s Next for Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 股價因 H5N1 新聞飆升——投資者接下來該怎麼辦？</li>
</ul>
</div><p>Merck &amp; Co., Inc. announced that its board has authorized a share repurchase program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.</p>
<div class="lb-trans"><p>默克公司宣佈其董事會於 1 月 28 日授權了一項股票回購計劃，授權公司回購 100 億美元的流通股。該回購授權允許公司通過公開市場購買最多 4.1% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
</div><h2>Merck &amp; Co., Inc. Dividend Announcement</h2>
<div class="lb-trans"><h2>默克公司分紅公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date is Monday, March 17th. Merck &amp; Co., Inc.'s dividend payout ratio (DPR) is 48.14%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項季度分紅，將於 4 月 7 日支付。3 月 17 日的登記投資者將獲得 0.81 美元的分紅。這相當於年化 3.24 美元的分紅，收益率為 3.84%。除息日為 3 月 17 日。默克公司的分紅支付比率（DPR）為 48.14%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 11/4 - 11/8</li>
</ul>
</div><p>Several research analysts have recently weighed in on the stock. Daiwa America cut shares of Merck &amp; Co., Inc. from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, November 11th. TD Securities lowered Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $121.00 to $100.00 in a report on Monday. UBS Group decreased their price objective on Merck &amp; Co., Inc. from $125.00 to $120.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, January 8th. Morgan Stanley cut their price objective on Merck &amp; Co., Inc. from $113.00 to $106.00 and set an &#34;equal weight&#34; rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets reduced their target price on shares of Merck &amp; Co., Inc. from $105.00 to $96.00 and set a &#34;market perform&#34; rating for the company in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Merck &amp; Co., Inc. presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $117.06.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票發表了看法。大和證券在 11 月 11 日的研究報告中將默克公司的股票評級從 “強力買入” 下調至 “持有”。TD 證券將默克公司的評級從 “買入” 下調至 “持有”，並將其目標價從 121.00 美元下調至 100.00 美元。瑞銀集團在 1 月 8 日的研究報告中將默克公司的目標價從 125.00 美元下調至 120.00 美元，並對該股票給予 “買入” 評級。摩根士丹利在 2 月 5 日的研究報告中將默克公司的目標價從 113.00 美元下調至 106.00 美元，並對該公司給予 “同等權重” 評級。最後，BMO 資本市場在 2 月 5 日的報告中將默克公司的目標價從 105.00 美元下調至 96.00 美元，並對該公司給予 “市場表現” 評級。一位股票研究分析師對該股票給予了賣出評級，十位分析師給予了持有評級，九位給予了買入評級，三位給予了強力買入評級。根據 MarketBeat 的數據，默克公司目前的共識評級為 “適度買入”，平均目標價為 117.06 美元。</p>
</div><p><strong>View Our Latest Report on MRK</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MRK 的最新報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, Director Inge G. Thulin bought 2,833 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was acquired at an average cost of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now owns 2,933 shares of the company's stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares in the company, valued at $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Inge G. Thulin 於 2 月 6 日的交易中購買了 2,833 股公司的股票。該股票的平均購買成本為每股 88.25 美元，總價值為 250,012.25 美元。收購完成後，該董事現在擁有 2,933 股公司的股票，價值約為 258,837.25 美元。這代表其持股增加了 2,833.00%。該交易已在證券交易委員會的法律文件中披露，可以通過 SEC 網站訪問。此外，內部人士 Cristal N. Downing 在 2 月 6 日的交易中出售了 2,361 股公司的股票。該股票的平均售價為 88.76 美元，總價值為 209,562.36 美元。交易完成後，該內部人士現在直接擁有 7,085 股公司股票，價值為 628,864.60 美元。該交易代表其持股減少了 24.99%。該銷售的披露信息可以在此找到。公司內部人士持有公司股票的 0.09%。</p>
</div><h2>Institutional Investors Weigh In On Merck &amp; Co., Inc.</h2>
<div class="lb-trans"><h2>機構投資者對默克公司的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of the stock. E&amp;G Advisors LP raised its position in Merck &amp; Co., Inc. by 0.7% in the 3rd quarter. E&amp;G Advisors LP now owns 14,698 shares of the company's stock valued at $1,669,000 after purchasing an additional 100 shares during the last quarter. Massachusetts Wealth Management increased its stake in Merck &amp; Co., Inc. by 0.4% in the third quarter. Massachusetts Wealth Management now owns 22,474 shares of the company's stock valued at $2,552,000 after purchasing an additional 100 shares during the period. Shayne &amp; Jacobs LLC raised its holdings in shares of Merck &amp; Co., Inc. by 1.8% in the third quarter. Shayne &amp; Jacobs LLC now owns 5,611 shares of the company's stock valued at $637,000 after buying an additional 100 shares during the last quarter. Alan B Lancz &amp; Associates Inc. boosted its stake in shares of Merck &amp; Co., Inc. by 0.7% during the third quarter. Alan B Lancz &amp; Associates Inc. now owns 13,834 shares of the company's stock worth $1,571,000 after buying an additional 100 shares during the period. Finally, First Bank &amp; Trust boosted its stake in shares of Merck &amp; Co., Inc. by 1.1% during the third quarter. First Bank &amp; Trust now owns 8,995 shares of the company's stock worth $1,021,000 after buying an additional 101 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>最近，一些機構投資者和對沖基金買賣了該股票的股份。E&amp;G Advisors LP 在第三季度將其在默克公司的持股比例提高了 0.7%。E&amp;G Advisors LP 現在擁有 14,698 股該公司的股票，價值 1,669,000 美元，此前在上個季度又購買了 100 股。馬薩諸塞州財富管理公司在第三季度將其在默克公司的股份增加了 0.4%。馬薩諸塞州財富管理公司現在擁有 22,474 股該公司的股票，價值 2,552,000 美元，此前在此期間又購買了 100 股。Shayne &amp; Jacobs LLC 在第三季度將其在默克公司的持股提高了 1.8%。Shayne &amp; Jacobs LLC 現在擁有 5,611 股該公司的股票，價值 637,000 美元，此前在上個季度又購買了 100 股。Alan B Lancz &amp; Associates Inc.在第三季度將其在默克公司的股份提高了 0.7%。Alan B Lancz &amp; Associates Inc.現在擁有 13,834 股該公司的股票，價值 1,571,000 美元，此前在此期間又購買了 100 股。最後，First Bank &amp; Trust 在第三季度將其在默克公司的股份提高了 1.1%。First Bank &amp; Trust 現在擁有 8,995 股該公司的股票，價值 1,021,000 美元，此前在此期間又購買了 101 股。76.07% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Merck &amp; Co., Inc. Company Profile</h2>
<div class="lb-trans"><h2>默克公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Merck &amp; Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.</p>
<div class="lb-trans"><p>默克公司是一家醫療保健公司，提供通過處方藥、疫苗、生物治療、動物健康和消費者護理產品的健康解決方案。它通過以下幾個部門運營：製藥、動物健康和其他。製藥部門包括人類健康藥品和疫苗產品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Merck &amp; Co., Inc.</li>
<li>Learn Technical Analysis Skills to Master the Stock Market</li>
<li>Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Buffett Buys More Occidental Petroleum—Sticking to His Playbook</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過默克公司。</li>
<li>學習技術分析技能，掌握股市。</li>
<li>Upstart 的上升趨勢剛剛開始：是時候加倉了。</li>
<li>投資者需要知道的擊敗市場的信息。</li>
<li>Archer Aviation 獲得黑石投資——ACHR 的下一步是什麼？</li>
<li>如何投資藍籌股。</li>
<li>巴菲特增持西方石油——堅持他的投資策略。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Where Should You Invest $1,000 Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 嗎？</h2>
</div><p>Before you make your next trade, you'll want to hear this.</p>
<div class="lb-trans"><p>在你進行下一筆交易之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。</p>
</div><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p>
<div class="lb-trans"><p>我們的團隊已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而且沒有一隻大名鼎鼎的股票在名單上。</p>
</div><p>They believe these five stocks are the five best companies for investors to buy now...</p>
<div class="lb-trans"><p>他們認為這五隻股票是投資者現在應該購買的五家最佳公司……</p>
</div><p>See The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在默克公司嗎？</h2>
</div><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮默克公司之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而默克公司不在名單上。</p>
</div><p>While Merck &amp; Co., Inc. currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然默克公司目前在分析師中有 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

交易員大量買入默克公司（紐約證券交易所代碼：MRK）的看跌期權